These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 8395493)

  • 1. Comparison of the mechanism of action and resistance of two new fluoroquinolones, rufloxacin and MF961 with those of ofloxacin and fleroxacin in gram-negative and gram-positive bacteria.
    Piddock LJ; Panchal S; Norte V
    J Antimicrob Chemother; 1993 Jun; 31(6):855-63. PubMed ID: 8395493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of action of sparfloxacin against and mechanism of resistance in gram-negative and gram-positive bacteria.
    Piddock LJ; Zhu M
    Antimicrob Agents Chemother; 1991 Nov; 35(11):2423-7. PubMed ID: 1666499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin.
    Barry AL; Fuchs PC
    J Chemother; 1997 Feb; 9(1):9-16. PubMed ID: 9106012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of enoxacin versus ciprofloxacin, fleroxacin, lomefloxacin, ofloxacin, pefloxacin, and rufloxacin against uropathogens.
    Naber KG; Well M; Hollauer K; Kirchbauer D; Witte W
    Chemotherapy; 1998; 44(2):77-84. PubMed ID: 9551236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter in vitro comparative study of fluoroquinolones against 25,129 gram-positive and gram-negative clinical isolates.
    Prosser BL; Beskid G
    Diagn Microbiol Infect Dis; 1995 Jan; 21(1):33-45. PubMed ID: 7789095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative activity of the new fluoroquinolone rufloxacin (MF 934) against clinical isolates of gram-negative and gram-positive bacteria.
    Qadri SM; Ueno Y; Postle G; Tullo D; San Pedro J
    Eur J Clin Microbiol Infect Dis; 1993 May; 12(5):372-7. PubMed ID: 8394816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of Bay y3118 against quinolone-susceptible and -resistant gram-negative and gram-positive bacteria.
    Piddock LJ; Marshall AJ; Jin YF
    Antimicrob Agents Chemother; 1994 Mar; 38(3):422-7. PubMed ID: 8203834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter study on the comparative in vitro activity of fleroxacin and three other quinolones: an interim report from 27 centers.
    Beskid G; Prosser BL
    Am J Med; 1993 Mar; 94(3A):2S-8S. PubMed ID: 8383919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The comparative activity of fleroxacin, three other quinolones and eight unrelated antimicrobial agents.
    McCarter YS; Mazens-Sullivan MF; Bartlett RC
    Chemotherapy; 1992; 38(5):308-18. PubMed ID: 1337507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-resistance analysis for clinafloxacin compared with ciprofloxacin, fleroxacin, ofloxacin, and sparfloxacin using a predictor panel of ciprofloxacin-resistant bacteria.
    Cormican MG; Jones RN
    J Antimicrob Chemother; 1995 Aug; 36(2):431-4. PubMed ID: 8522474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative antimicrobial activity and spectrum of CP-99,219, a novel fluoroquinolone, tested against ciprofloxacin-resistant clinical isolates.
    Murphy SP; Cormican MG; Jones RN
    Ir J Med Sci; 1995; 164(4):271-3. PubMed ID: 8522427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of T-3761, a new fluoroquinolone.
    Muratani T; Inoue M; Mitsuhashi S
    Antimicrob Agents Chemother; 1992 Oct; 36(10):2293-303. PubMed ID: 1332594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-vitro and in-vivo activities of DW-116, a new fluoroquinolone.
    Choi KH; Hong JS; Kim SK; Lee DK; Yoon SJ; Choi EC
    J Antimicrob Chemother; 1997 Apr; 39(4):509-14. PubMed ID: 9145824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of E-4868, a new fluoroquinolone with a 7-azetidin ring, compared with ciprofloxacin, ofloxacin and fleroxacin.
    Mirelis B; Navarro F; Miró E; Coll R; Xicota MA; Prats G
    Drugs Exp Clin Res; 1995; 21(4):129-38. PubMed ID: 8529525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of increasing levels of quinolone resistance on in-vitro activity of four quinolones.
    Thomson KS; Sanders CC
    J Antimicrob Chemother; 1998 Aug; 42(2):179-87. PubMed ID: 9738835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones.
    Montanari MP; Prenna M; Mingoia M; Ripa S; Varaldo PE
    Chemotherapy; 1998; 44(2):85-93. PubMed ID: 9551237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative in vitro activity of fleroxacin, two other quinolones and three board-spectrum beta-lactams using the E-Test.
    Sobottka I; Neumann S; Laufs R
    Chemotherapy; 1994; 40(5):293-8. PubMed ID: 7956451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial activity evaluations of two new quinolones, PD127391 (CI-960 and AM-1091) and PD131628.
    Barrett MS; Jones RN; Erwin ME; Johnson DM; Briggs BM
    Diagn Microbiol Infect Dis; 1991; 14(5):389-401. PubMed ID: 1665774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [In vitro antibacterial activity of prulifloxacin, a new oral fluoroquinolone].
    Araake M; Hara T; Watabe H; Nishino T
    Jpn J Antibiot; 2002 Dec; 55(6):778-90. PubMed ID: 12621732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dissociated resistance among fluoroquinolones.
    Thomson KS; Sanders CC
    Antimicrob Agents Chemother; 1994 Sep; 38(9):2095-100. PubMed ID: 7811025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.